Mammogen is a pioneering biotechnology company focused on revolutionizing the detection and diagnosis of breast cancer through innovative technologies. The company specializes in developing multi-gene expression signatures that utilize novel circulating messenger RNA (mRNA) biomarkers, which can be extracted from various biofluids, including blood and saliva. This approach allows for non-invasive testing that aims to provide earlier and more accurate detection of breast cancer, particularly for underserved populations such as women under 40 and those over 55. Mammogen's technology has demonstrated high sensitivity and specificity in clinical validations, positioning it as a significant advancement over traditional screening methods.

In addition to its focus on early detection, Mammogen emphasizes the importance of understanding the real-time biological responses of patients through transcriptomics. By analyzing RNA expression, the company aims to gain insights into the current state of disease processes, moving beyond the limitations of circulating tumor DNA (ctDNA) biomarkers, which reflect past conditions rather than the present state of the disease. This innovative approach not only enhances diagnostic accuracy but also aims to foster a supportive community for women facing health challenges, ultimately striving to improve the overall quality of care and outcomes in women's health.

United States

Mammogen is a liquid biopsy company on a mission to unlock the quality-of-life preservation that exists at the earliest stages of diseases that affect women's health, starting with breast cancer.

Mammogen

Company Details